Palvella Therapeutics Posts Wider Q2 Loss of $1.52/Shr
PVLA has more than doubled off its 52-week low of $34.57.
Summary
Palvella Therapeutics reported a Q2 loss of $1.52 per share, widening from $1.20 in the prior quarter, driven by higher expenses. The increased loss reflects ongoing R&D investment, consistent with the company's clinical-stage profile. This follows a series of positive clinical data announcements and a recent $215.8M equity raise that extended its cash runway. The loss is not unexpected for a biotech advancing its pipeline, but the sequential increase may pressure shares given the high cash burn. Upcoming catalysts include the NDA submission for QTORIN rapamycin in microcystic LMs, as noted in the July corporate presentation.
At the time of this announcement, PVLA was trading at $140.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $34.57 to $161.38. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.